肾性贫血的药物治疗进展  

Progress in pharmacotherapy of anemia in chronic kidney disease

作　　者：陈威宇 毕书红[2] 唐子勇[2] CHEN Wei-yu;BI Shu-hong;TANG Zi-yong(Department of Internal Medicine,Pelking University Third Hospital,Beijing 100191,China;Department of Nehprology,Pelking University Third Hospital,Beijing 100191,China)

机构地区：[1]北京大学第三医院临床医学内科学系,北京100191 [2]北京大学第三医院肾内科,北京100191

出　　处：《临床药物治疗杂志》2019年第12期20-24,共5页Clinical Medication Journal

摘　　要：肾性贫血是慢性肾脏病的常见并发症,与慢性肾脏病患者预后密切相关。肾性贫血目前的治疗主要集中在促红细胞生成素替代和补充铁剂2个方面,临床上存在贫血患病率高、达标率低等问题。近年来,新兴的铁剂、促红细胞生成素制剂以及针对肾性贫血发病机制新靶点的治疗手段不断用于临床,为肾性贫血的治疗提供了新的选择。本文从肾性贫血的发病机制出发,综述了肾性贫血的药物治疗进展。Anemia is a common complication of chronic kidney disease(CKD),and strongly related to the prognosis of CKD.Current pharmacotherapy consists of iron and erythropoiesis-stimulating agent.Prevalence study showed a high prevalence of anemia and a low control rate of standard in clinical practice.In recent years,new iron agent,erythropoiesis-stimulating agent and new therapeutic methods aiming at the new target of renal anemia pathogenesis are constantly used in clinical,which provides a new choice for the treatment of renal anemia.The purpose of this review is to highlight the progress in pharmacotherapy of anemia in CKD.

关 键 词：肾性贫血 药物治疗 铁剂 促红细胞生成素 缺氧诱导因子脯氨酰羟化酶抑制剂 铁调素 

分 类 号：R973.3[医药卫生—药品]